Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBITDA (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBITDA for 13 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 133.75% to $3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.7 million, a 175.83% increase, with the full-year FY2024 number at -$9.2 million, up 80.39% from a year prior.
  • EBITDA was $3.7 million for Q3 2025 at Theravance Biopharma, down from $54.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $916.6 million in Q3 2022 to a low of -$79.7 million in Q1 2021.
  • A 5-year average of $37.4 million and a median of -$13.6 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 2696.33% in 2022, then crashed 100.97% in 2023.
  • Theravance Biopharma's EBITDA stood at -$35.3 million in 2021, then soared by 50.62% to -$17.4 million in 2022, then surged by 49.01% to -$8.9 million in 2023, then decreased by 3.5% to -$9.2 million in 2024, then soared by 139.75% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBITDA are $3.7 million (Q3 2025), $54.8 million (Q2 2025), and -$13.6 million (Q1 2025).